These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20388767)

  • 1. Mepolizumab in refractory eosinophilic asthma.
    Pavord ID; Haldar P; Bradding P; Wardlaw AJ
    Thorax; 2010 Apr; 65(4):370. PubMed ID: 20388767
    [No Abstract]   [Full Text] [Related]  

  • 2. Mepolizumab in corticosteroid-resistant eosinophilic asthma.
    Barratt S
    Thorax; 2009 Jun; 64(6):552. PubMed ID: 19478129
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 4. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of severe eosinophilic asthma and refractory rheumatoid arthritis well controlled by combination of IL-5Rα antibody and TNFα inhibitor.
    Yamada H; Hida N; Kurashima Y; Satoh H; Saito T; Hizawa N
    Allergol Int; 2019 Oct; 68(4):536-538. PubMed ID: 31027977
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy.
    Howarth P; Chupp G; Nelsen LM; Bradford ES; Bratton DJ; Smith SG; Albers FC; Brusselle G; Bachert C
    J Allergy Clin Immunol; 2020 Jun; 145(6):1713-1715. PubMed ID: 32084443
    [No Abstract]   [Full Text] [Related]  

  • 8. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
    Albers FC; Price RG; Smith SG; Yancey SW
    J Allergy Clin Immunol; 2017 Nov; 140(5):1464-1466.e4. PubMed ID: 28687231
    [No Abstract]   [Full Text] [Related]  

  • 9. Mepolizumab for Treatment of Severe Eosinophilic Asthma: A 5-Year Real-World Experience.
    Loli-Ausejo D; Perdomo G; Mascaró B; Martínez-Olondris P; Sánchez-Fernández MC; Mullol J; Valero A; Arismendi E; Bobolea I
    J Investig Allergol Clin Immunol; 2023 Jun; 33(3):209-210. PubMed ID: 36820628
    [No Abstract]   [Full Text] [Related]  

  • 10. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
    Weir E; Paton J
    J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
    [No Abstract]   [Full Text] [Related]  

  • 11. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma.
    Yancey SW; Ortega HG; Keene ON; Mayer B; Gunsoy NB; Brightling CE; Bleecker ER; Haldar P; Pavord ID
    J Allergy Clin Immunol; 2017 Apr; 139(4):1167-1175.e2. PubMed ID: 27726946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
    Cormier M; Chaboillez S; Lemiere C
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):736-738. PubMed ID: 31421278
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.
    Shimizu Y; Kurosawa M; Sutoh Y; Sutoh E
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):154-155. PubMed ID: 31778113
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia.
    Sato H; Miyata Y; Inoue H; Tanaka A; Sagara H
    J Investig Allergol Clin Immunol; 2021 Oct; 31(5):459-460. PubMed ID: 33502319
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging Therapies in Severe Eosinophilic Asthma.
    Pang PH; Brightling CE
    Arch Bronconeumol; 2017 May; 53(5):233-234. PubMed ID: 28279518
    [No Abstract]   [Full Text] [Related]  

  • 16. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
    Howarth P; Quirce S; Papi A; Israel E; Mallett S; Bates S; Yancey S; Albers FC; Kwon N
    Allergy; 2020 Aug; 75(8):2085-2088. PubMed ID: 32147844
    [No Abstract]   [Full Text] [Related]  

  • 17. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
    Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
    Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological treatment is approved for severe eosinophilic asthma.
    Mayor S
    BMJ; 2016 Nov; 355():i6472. PubMed ID: 27908911
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis.
    Lugogo N; Liu MC; Pavord I; Mitchell PD; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Bel EH
    J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3506-3509.e3. PubMed ID: 34111572
    [No Abstract]   [Full Text] [Related]  

  • 20. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
    Strauss RA; Jawhari N
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.